Role of Inflammation on the Control of the Arterial Hypertension among Patients with Metabolic Syndrome.

Ylber Jani MD, PhD 1, Atila Rexhepi MD, PhD 2, Bekim Pocesta MD 3, Ahmet Kamberi MD, PhD 4, Fatmir Ferati MD, PhD 5, Sotiraq Xhunga MD, PhD 6, Artur Serani MD 7, Dali Lala MD 8, Agim Zeqiri MD 9, Arben Mirto MD 10, Lutfi Zylberi 11.

1Faculty of Medicine, Tetovo Republic of North Macedonia.
2Department of Internal Medicine Faculty of Medicine, Tetovo Republic of North Macedonia.
3Department of Cardiology Faculty of Medicine “Ss Kiril and Metodij” University Skopje Republic of North Macedonia.
4Department of Cardiology Faculty of Medicine M. Teresa Tirana Republic of Albania.
5Department of Internal Medicine Faculty of Medicine, Tetovo Republic of North Macedonia.
6Department of Cardiology Medical Center Dures Republic of Albania.
7Private Health Institute of family medicine "Florenc “Tetovo Republic of North Macedoniana.
8Department of Internal Medicine-General Hospital"DR Ferit Murat” Gostivar Republic of North Macedonia. 9Private Health Institute"Rostusha”Debar Republic of North Macedonia.
11Faculty of Medicine, Tetovo Republic of North Macedonia.

*Corresponding Author: Ylber Jani, Faculty of Medicine, Tetovo Republic of North Macedonia.

Received: January 21, 2020; Accepted: February 03, 2020; Published: February 07, 2020

Citation: Jani Y., Rexhepi A., Pocesta B., Kamberi A., Ferati F., et al. (2020) Role of inflammation on the control of the arterial hypertension among patients with metabolic syndrome. J. Clinical Cardiology and Cardiovascular Interventions, 3(3); Doi:10.31579/2641-0419/044

Copyright: © 2020 Ylber Jani, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: It is widely accepted that hypertension is a pro-inflammatory disease and that the immune system plays a vital role in mediating hypertensive outcomes, end organ damages. And modulation of hypertensive pathology [2]. Patient with MetS usually present increased levels of C-reactive protein (CRP) which is a prototypical marker of inflammation [5], however the data of the influence of increased levels of CRP on the control of the arterial hypertension in patients with MetS, are scarce.

Objective: We sought to determine the increased CRP levels influence on the control of the arterial hypertension in patients with MetS.

Methods: We conducted a multicenter observational cross-sectional study. The study population recruited from a couple of outpatient clinic between June 2018 and June 2019. The population study consisted of 420 patients with MetS aged ≥ 18 years, divided in two groups: 211 with level of CRP >3mg/l, and 209 participants with CRP level <3mg/l.

Results: Among those with CRP level >3mg/l (N=211) controlled BP according to evidence and current guidelines, was achieved in 23.6% of participants, whereas among those with CRP level <3mg/l(N=209) controlled BP was achieved in 48.3%; p=0.000. There was independent association of CRP levels >3mg/l with uncontrolled BP (OR=3.1, 95%CI 2.06 - 4.75). There were significant association of uncontrolled BP with: uncontrolled glycaemia (OR =1.4, 95%CI 0.97-1.84); increased BMI (OR=4.4; 95%CI 3.02-4.05) and five risk factors for MetS. (OR=2.3, 95%CI 1.93-2.81).

Conclusions: We think, we brought some good evidence, in our present study, that patients with MetS and higher CRP level have a higher prevalence of uncontrolled BP.

Key words: C-reactive protein; control of BP in patient with Metabolic Syndrome.

Used abbreviations in the text:

MetS – Metabolic Syndrome
CRP – C-reactive protein
BW – Body weight
BMI – Body mass index
BP – Blood pressure
SBP – Systolic blood pressure
DBP – Diastolic blood pressure
T2DM – Diabetes Mellitus type 2
WCi – Waist circumference
HDL-C – High density lipoproteins cholesterol
TG – serum triglycerides

ESC/ESH -- European society of Cardiology /European society of Hypertension

Introduction

Despite enhanced screening and therapeutic management, hypertension remains the most prevalent chronic disease worldwide and the leading cause of heart disease, chronic kidney disease, and stroke in both men and women 1. In recent years, a vast body of evidence has accumulated indicating the role of the immune system in the regulation of blood pressure and modulation of hypertensive pathology. It is widely accepted that hypertension is a pro-inflammatory disease and that the immune system plays a vital role in mediating hypertensive outcomes and end organ damages [2].
Metabolic syndrome (Mts), is a cluster of metabolic risk factors that includes high blood pressure, hyperglycemia, dyslipidemia and abdominal obesity, has been an increasing health problem worldwide for the last three decades, is associated with adverse cardiac events [3]. Patient with Mts usually present increased levels of C-reactive protein (CRP) which is a prototypic marker of inflammation[4], however the influence of increased levels of CRP on control of arterial hypertension in patients with Mts, data are scarce.

We set out to determine the influence of inflammation (assessed by increased levels of CRP) on control of arterial hypertension in patients with Mts. We set out to test the hypothesis: Patients with Mts and high level of CRP have higher prevalence of uncontrolled arterial hypertension than patients with Mts and lower level of CRP. These findings might lend further insight into inflammation-immune reactivity in arterial hypertension strategies for the control of arterial hypertension in patients with Mts.

Objective

We sought to determine the influence increased levels of CRP on control of arterial hypertension in patients with Mts.

Methods

Study design.

We conducted a multicenter observational cross-sectional study. The study population was recruited from our outpatient clinic between June 2018 and June 2019. Subjects who fulfilled the criteria for Mts according to the results of recent laboratory tests were prospectively evaluated.

The population consisted of 420 patients with Mts aged ≥18 years, divided into two groups: 211 participants (100 females and 111 males) with level of CRP≥3mg/l, and 209 participants (104 females and 105 males) with level of CRP<3mg/l.

All participants underwent a comprehensive medical history and physical examination. Resting ECG, anthropometrics, measuring of blood pressure according to standard protocol (obtained after 10 min of rest in the sitting position, expressed as the average of 3 consecutive measurements), the mean systolic and diastolic blood pressure recording during the study period, were calculated. Hypertension was defined be current ESC/ESH guidelines for the management of arterial hypertension as office systolic blood pressure (SBP) values ≥140 mmHg, and/or diastolic blood pressure (DBP) values ≥90 mmHg and/or current anti-hypertensive therapy [5].

Uncontrolled BP, was defined defined by current ESC/ESH guidelines for the management of arterial hypertension [5]. The blood pressure was considered to be controlled if the calculated mean systolic and diastolic blood pressure recording during the study period was found to be less than 140/90mmHg. Among adults younger than 60 years and less than 150/90mmHg in general population aged ≥60 years. Diabetes mellitus was defined as a fasting serum glucose level ≥126 mg/dl and/or current medical therapy with an oral hypoglycemic agent and/or insulin[6].

Body mass index (BMI) was calculated as weight (kg) divided by the square of the height (m²). Weight was measured with weight balance scales, and height with stadiometer. Waist circumference WCi, was reported in cm.

An overnight fasting blood sample, was drawn from each patient to determine: blood glucose, lipid profile tests total serum cholesterol (TC), serum High density lipoproteins cholesterol (HDL-C), serum triglycerides (TG). The sample analysis was performed using standard biochemical analytical methods. Plasma CRP levels was measured using latex particle-enhanced immunosassay with the nephelometry (Roche Swiss). Consistent with recommendations from Centers for Disease Control and Prevention [7] (a CRP cutoffpoint of 3.0mg/L), was used to differentiate high-risk and low-risk group.

Exclusion criteria, included a diagnosis of dementia senilis, secondary hypertension, serum creatinine level >2mg/dl, age under 18 years and over 79 years.

Mts was defined according to the harmonized definition of the International Diabetes Federation and other organizations [8], that three or more out of five following criteria are considered as Mts: (1) central adiposity [Waist circumference (WCi)] >102 cm in men and >88cm in women [9]; (2) serum HDL-C < 50 mg/dl in women or < 40 mg/dl in men; (3) serum triglyceride levels >150 mg/dl; (4) SBP ≥140mmHg or DBP ≥90mmHg or use of antihypertensive drugs; (5) the presence of diabetes mellitus (DM) or use of anti-diabetic drugs. A standardized case report form was used to collect data from medical record and was sent to the central data management unit.

The study is in compliance with the Declaration of Helsinki. All patient that participated in this study were written informed, consent was obtained from all participating patients before they were enrolled into the study.

Statistical Analysis

Results are expressed as mean and ±SD, or as percentage. A simple descriptive analysis was performed for the general characterization of the sample and distribution of variables. The distribution of variables was tested for normality using the Kolmogorov Smirnov test, and the heterogeneity of variances was evaluated by Levene's test. To compare baseline characteristics and echocardiographic findings between groups, we used Student's unpaired *t* test for continuous data, Mann-Whitney U*test* for continuous data with abnormal distribution, and *X²*-test for categorical data. The association between variables were analyzed using logistic regression. Odds ration (OR) and 95% confidence interval (CI) were estimated by logistic regression. A, p value <0.05 was considered statistically significant for a confidence interval of 95%. Data were coded, entered and analysed using SPSS software package (SPSS 19.0).

Results:

A total of 420 subjects with Mts enrolled in our study, stratified in two groups: 209 participants (47.5% females and 52.5% males) with level of CRP < 3mg/l, and 211 participants (47% females and 53% males) with level of CRP > 3mg/l, completed the survey and had data for 1-year medical record review. A mean of 3.4 BP recordings were obtained for each participants.

Baseline demographic, anthropometric and laboratory, characteristics by group are displayed in (Table 1)
In a logistic regression (Table 3), there was independent association of CRP levels >3mg/l with uncontrolled BP (OR=3.1, 95%CI: 2.06 - 4.75). There were significant association of uncontrolled BP with: uncontrolled glycemia (OR =1.4, 95%CI: 0.97-1.84); increased BMI (OR=4.4; 95%CI: 3.02-4.05) and five risk factors for MetS. (OR=2.3, 95%CI:1.93-2.81).

### Table 1: Basic demographic, anthropometric and laboratory characteristics of study population. (MetS N=420).

| Variables                  | Gr-I. CRP < 3mg/l (N=209) | Gr.II. CRP > 3mg/l (N=211) | p-value |
|----------------------------|----------------------------|----------------------------|---------|
|                            | N. (%)        | Men ±SD | N. (%)        | Mean ±SD |         |
| Gender                     |               |         |               |         |         |
| Females                    | 104 (47.8)    |         | 100 (47%)     |         | 0.77    |
| Males                      | 105 (50.2)    |         | 111 (53%)     |         | 0.78    |
| Age (year)                 | 61.6 ±8.6     | 60.4 ±9.3 | 0.11         |         |
| BMI (kg/m²)                | 25.6 ±4.2     | 31.1 ±4.7 | 95% CI for Exp (B) |         |
| SBP (mmHg)                 | 132.3 ±18.5   | 140.7 ±14.5 | 0.000        |         |
| DBP (mmHg)                 | 80.5 ±4.5     | 85.7 ±5.8 | 95% CI for Exp (B) |         |
| T2DM (p)                   | 159 (76.1)    |         | 146 (69.1)    | 0.52    |
| WCi (cm.)                  | 160 (76.5)    | 95.8 ±7.8 | 181 (85.7)    | 102.3 ±3.8 | 0.00    |
| HDL-C (p: mmol/l)          | 143 (68.4)    | 0.92 ±0.1 | 158 (74.1)    | 0.95 ±0.01 | 0.36    |
| Trig. (p:mmol/l)           | 124 (59.3)    | 2.01 ±0.2 | 147 (69.6)    | 2.08 ±0.1 | 0.11    |
| glyc.(con; mmol/l)         | 133 (63.6)    | 6.4 ±0.8 | 81 (38.3)     | 6.8 ±0.6 | 0.003   |
| CRP (mg/l)                 | 2.7 ±0.1      | 7.7 ±2.5 | 95% CI for Exp (B) |         |
| Three MetS. risk factor    | 140 (66.9)    | 101 (47.8) | 0.003        |         |
| Four MetS. risk factor     | 55 (26.3)     | 72 (34.1) | 0.2          |         |
| Five MetS. risk factor     | 14 (6.7)      | 38 (18) | 0.000        |         |

Table 2. Frequency of controlled BP among patients with MetS stratified by CRP levels (No.420).

| Frequency of controlled BP | Gr-I. (CRP< 3mg; No. 209) | Gr. II. (CRP > 3mg; No. 211) |
|----------------------------|---------------------------|------------------------------|
| Count (No.)                | 101                       | 50                           |
| Percent (%)                | 48.3                      | 23.6                         |

BP: blood pressure; MetS-RF n.5: five risk factors for MetS; DM: Diabetes Mellitus; BMI: Body mass index. OR* >1.
Discussion:

In this study we found that patients with MetS and higher levels of CRP had significantly higher prevalence of uncontrolled BP than did those with MetS and lower levels of CRP. Results that confirmed our hypothesis. Low-grade inflammation is now a recognized hallmark of hypertension, and therein is an expanding literature regarding the role of inflammation and inflammatory cells in hypertension, in particular T lymphocytes are now thought to have a central role in the development of hypertension and related organ injury. Based on the central role played by the cytokine milieu in determining lymphocyte differentiation and activation, differences of cytokines levels likely contribute to observed difference on the prevalence of uncontrolled BP in present study, and will impact the overall physiological outcome of an inflammatory response. The CoLaus Study reported that serum CRP, interleukin-6 and THF-α levels were positively associated with BP [11,12]. Also, Grundy SM et al, suggests a significant association among inflammation, hypertension, and the metabolic syndrome [13]. Nevertheless, despite an association between high CRP levels and hypertension, a causal relationship has not been demonstrated. In fact, Smith et al. used a Mendelian randomization approach to examine a possible causal relationship analyzing the association of the 1059G/C polymorphism in the human CRP gene with hypertension, the work failed to confirm a causal relationship between CRP and blood pressure [14].

In our study, BP was controlled at 38% patient only. This result is consistent with previous findings that patients with hypertension and MS have an elevated prevalence of uncontrolled BP [15,16]. The study results allow evaluating the effffectivity of hypertension treatment as for drug choose, decrease of sBP and dBP associated with a certain drug, a drug combination, and therapeutic inertia in these patients.

We also found that BP control was worse among patients with MetS and higher CRP levels in the presence of more MetS risk factors. It appears that there is an interaction between hypertension and metabolic disorder factors, although the mechanisms that are involved in this interaction remain unclear. Results in present study are consistent with previous findings [17]. It has been suggested that metabolic disorder factors have additive effects on BP control and cardiovascular disease. Arcucci et al. have reported that BP control worsens in the presence of more metabolic disorder factors [17] These data suggest that presence of more metabolic disorder factors, decrease the probability of BP control. We found association of number of risk factors of MetS and higher levels of CRP. However, it is unknown whether the number of MetS risk factors can influence the levels of CRP. Previous study demonstrated that number of risk factors did not influence the levels of CRP in patients with MetS [18]. Also in present study we found association of higher levels of CRP in patient with uncontrolled BP and elevated levels of triglycerides, low HDL levels, obesity and uncontrolled glycemia. Results in present study are consistent with previous findings [19-21].

Study limitations

The study employed a cross-sectional design, and as such, the results could show only factors associated with uncontrolled hypertension. Study design limited to make causal inferences regarding increased CRP levels and control of arterial hypertension in patient with MetS. A larger sample would certainly increase the statistical power of the study, and probably some differences would therefore become more expressive. Despite some methodological limitations, this study clearly demonstrated a relationship between increased CRP levels and control of BP in patient with MetS.

Clinical Implications

These data provide further evidence that poor BP control is common in patients with MetS, and further investigations on the immune reactivity in hypotension may result in the identification of new strategies for the treatment of the disease. Therapeutic interventions to reduce activity of immunity may prove beneficial in reducing consequences of hypertension including: myocardial infarction, heart failure, renal failure and stroke.

Conclusions

We think, we brought some good evidence, in our present study, that patients with MetS and higher CRP level have a higher prevalence of uncontrolled BP. These results indicate that presence of an subclinical inflammatory process in the natural history of MetS, through presence of high CRP levels, negatively affect BP control in patients with MetS. Measurement of this inflammatory protein may help to determine individuals cardiovascular risk and activity of immune system, it might be a novel therapeutic target for the treatment of high blood pressure in these individuals.

Materials- Agim Zeqiri;Dali Lala, Fatmir Ferati;Arben Mirto;Data collection/pro cessing-Sotiraq Xhunga;Artur Serani;Ylber Jani; Analysis/interpretation-Ylber Jani;Ahmet Kamberi;Atilla Rexhepi; Bekim Pecosta;Literature Search- Ylber Jani;Agin Zeqiri;Dali Lala; Fatmir Ferati;Artur Serani. Critical Reviews-Ahmet Kamberi.

All authors read and approved the final manuscript.

The authors reported no conflict of interest and no funding has been received on this work.

References:

1. Heart Disease and Stroke Statistics 2019. Update: a report from the American Heart Association. Circulation. 2019;139:e56–528.
2. Tomasz P. Mikolajczyk, Tomasz J. Guzik TJ et al. (2019) Adaptive Immunity in Hypertension. Current Hypertension Reports. September:21:68.
3. Ford ES. (2005) Prevalence of the Metabolic Syndrome Defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 28(11):2745–2749.
4. Haffner SM. (2006) The metabolic syndrome:inflammation,diabetes mellitus and cardiovascular disease. Am J Cardiol. 97(2A);3A-11A.
5. Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, Volume 39, Issue 33, Pages 3021–3104.
6. America Diabetes Association. Standards for medical care for patient with diabetes mellitus. Diabetes Care 2002;25 Suppl 1:S33–S49.
7. Center for disease control/American Heart association Workshop on inflammatory Markers, and Cardiovascular Disease: Application to clinical and public health practice: Atlanta, March 14-15,2002.Atlanta, Ga. Centers for Disease Control and Prevention:2002.
8. Ford ES, Li C, Zhao G. (2010) Prevalence and correlates of metabolic syndrome based on a harmonised definition among adults in the US. J Diabetes. 2(3):180–193.
9. Organisation WH. (2008) Weist circumference and waist –hip ratio:report of WHO expert consultation.Geneva 8-11,2011.
10. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A. et al. (2007) Role of the T cell in the genesis of angiotensin II
induced hypertension and vascular dysfunction. J Exp Med 204: 2449–2460.

11. Pruijm M, Vollenweider P, Mooser V, Paccaud F, Preisig. (2013) Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus Study. J Hum Hypertens 27: 169–175.

12. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, (2003) Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA. 290: 2945-2951.

13. Grundy SM (2003) Inflammation, hypertension, and the metabolic syndrome. JAMA. 290 (22): 3000-3002.

14. Smith GD, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S. (2005) Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 25: 1051–1056.

15. Kjeldsen, S. E., Naditch-Brule, L., Perlini, S., Zidek, W. & Farsang, C. (2008) Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. J Hypertens. 26, 2064–2070.

16. Jani Y, Kamberi A, Lala D et al. (2013) Control of Arterial Hypertension among type-2 Diabetics. International Journal of BioMedicine. 3(4):232-239.

17. Arcucci, O. et al. (2007) Association of suboptimal blood pressure control with body size and metabolic abnormalities. Journal of hypertension 25:2296–2300.

18. Garcia VP, Rocha HN, Sales AR, Rocha NG, da NObrega AC. (2016) Sex differences in High Sensitive C-Reactive Protein in subjects with Risk Factors of Metabolic Syndrome. Arq Bras Cardiol. 106 (3):182-187.

19. Ridker PM, Wilson PW, Grundy SM. (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 109: 2818-2825.

20. Sandhu, H. S., Koley, S. & Sandhu, K. S. A. (2008) Study of Correlation between Lipid Profile and Body Mass Index (BMI) in Patients with Diabetes Mellitus. J Hum Ecol. 24:227–229.

21. Matsuda, M. & Shimomura, I. (2013) Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obesity Research & Clinical Practice. 7:E330–E341.